Galmed Pharmaceuticals
GLMD
19 hedge funds and large institutions have $5.93M invested in Galmed Pharmaceuticals in 2015 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 1 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
0% more funds holding
Funds holding: 19 → 19 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
1% less capital invested
Capital invested by funds: $5.99M → $5.93M (-$60K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$51.1K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$25.5K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$25.5K |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$12.8K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$12.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$179K |
| 2 |
SKK
Shepherd Kaplan Krochuk
Boston,
Massachusetts
|
-$166K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$24K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$12.8K |
| 5 |
Morgan Stanley
New York
|
-$12.8K |
GLMD Hedge Fund Activity: Q4 2015 in Review
19 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q4 2015, worth a combined $5.93M — down 1% from $5.99M a quarter earlier.
Fund positioning in GLMD was balanced in Q4 2015: 1 fund opened new positions, 1 closed out, 5 added to existing stakes and 4 trimmed.
The largest buyer was DAFNA Capital Management, adding an estimated $51.1K. The largest seller was Goldman Sachs, cutting an estimated $179K.
- 19 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q4 2015, unchanged from Q3 2015.
- Funds reported $5.93M of Galmed Pharmaceuticals stock for Q4 2015, down 1% quarter-over-quarter.
- 1 fund opened new Galmed Pharmaceuticals positions in Q4 2015 and 1 closed out, a net change of 0 holders.
- The largest Galmed Pharmaceuticals buyer in Q4 2015 was DAFNA Capital Management, an estimated $51.1K added.
- The largest Galmed Pharmaceuticals seller in Q4 2015 was Goldman Sachs, an estimated $179K sold.
Based on aggregated 13F filings for Q4 2015.